Madrigal Pharmaceuticals Inc (MDGL)
212.09
-10.50
(-4.72%)
USD |
NASDAQ |
Apr 19, 16:00
212.09
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Cash from Investing (Quarterly): -362.12M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -362.12M |
September 30, 2023 | 50.20M |
June 30, 2023 | -3.732M |
March 31, 2023 | -186.86M |
December 31, 2022 | 66.39M |
September 30, 2022 | 65.14M |
June 30, 2022 | 19.24M |
March 31, 2022 | 55.93M |
December 31, 2021 | 15.64M |
September 30, 2021 | 40.09M |
June 30, 2021 | -27.32M |
March 31, 2021 | -33.46M |
December 31, 2020 | -4.798M |
September 30, 2020 | 94.75M |
June 30, 2020 | 19.36M |
March 31, 2020 | 50.46M |
December 31, 2019 | -30.51M |
September 30, 2019 | 28.27M |
June 30, 2019 | 36.44M |
March 31, 2019 | -3.491M |
December 31, 2018 | 24.99M |
September 30, 2018 | -222.03M |
June 30, 2018 | -80.91M |
March 31, 2018 | -102.12M |
December 31, 2017 | 6.085M |
Date | Value |
---|---|
September 30, 2017 | -16.89M |
June 30, 2017 | -0.647M |
March 31, 2017 | -10.56M |
December 31, 2016 | 10.08M |
September 30, 2016 | 11.92M |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.00 |
December 31, 2015 | 0.00 |
September 30, 2015 | 14.70M |
June 30, 2015 | -23.02M |
March 31, 2015 | 8.317M |
December 31, 2014 | -0.93M |
September 30, 2014 | -35.58M |
June 30, 2014 | 11.48M |
March 31, 2014 | 16.20M |
December 31, 2013 | -15.15M |
September 30, 2013 | 8.493M |
June 30, 2013 | 18.62M |
March 31, 2013 | -36.62M |
December 31, 2012 | 6.52M |
September 30, 2012 | -6.839M |
June 30, 2012 | 3.697M |
March 31, 2012 | -13.32M |
December 31, 2011 | 19.99M |
September 30, 2011 | 6.708M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-362.12M
Minimum
Dec 2023
94.75M
Maximum
Sep 2020
-5.627M
Average
19.36M
Median
Jun 2020
Cash from Investing (Quarterly) Benchmarks
Eli Lilly and Co | -2.924B |
Viking Therapeutics Inc | 35.73M |
Akero Therapeutics Inc | 12.79M |
89bio Inc | -63.64M |
Geron Corp | 47.57M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -79.93M |
Cash from Financing (Quarterly) | 479.92M |
Free Cash Flow | -325.71M |
Free Cash Flow Per Share (Quarterly) | -4.095 |
Free Cash Flow Yield | -8.22% |